Research and publications
Clinical studies
Conducted phase 1 and phase 2 studies demonstrate good efficacy and safety for BupiZenge®. In phase 2, it was shown* that BupiZenge® reduced mouth pain by 50% compared to standard treatment (p=0.0002). In the combined efficacy variable, pain in the mouth and throat decreased by 31% (p=0.0032). Few and mild side effects, no serious side effects.
*Refer to publications, Pain Reports 2017.”
Mouth and throat
Only mouth
Publications
Effect of bupivacaine lozenges on oral mucositis pain: a randomized controlled multicenter phase II study.
Mogensen S, Treldal C, Kristensen CA, Bentzen J, Lawson-Smith L, Petersen J, Andersen O.Pain Rep. 2017 Aug 23;2(5):e619. doi: 10.1097/PR9.0000000000000619. eCollection 2017 Sep.PMID: 29392234 Free PMC article.
A novel lozenge containing bupivacaine as topical alleviation of oral mucositis pain in patients with head and neck cancer: a pilot study.
Mogensen S, Treldal C, Sveinsdottir K, Jensen K, Kristensen CA, Mogensen TS, Petersen J, Andersen O.Pain Rep. 2016 Sep 30;1(3):e571. doi: 10.1097/PR9.0000000000000571. eCollection 2016 Sep.PMID: 29392194 Free PMC article.
Absorption of Bupivacaine after Administration of a Lozenge as Topical Treatment for Pain from Oral Mucositis.
Mogensen S, Sverrisdóttir E, Sveinsdóttir K, Treldal C, Jensen K, Jensen AB, Kristensen CA, Jacobsen J, Kreilgaard M, Petersen J, Andersen O.Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):71-78. doi: 10.1111/bcpt.12644. Epub 2016 Sep 26.PMID: 27430990 Free article. Clinical Trial.
Bupivacaine Lozenge Compared with Lidocaine Spray as Topical Pharyngeal Anesthetic before Unsedated Upper Gastrointestinal Endoscopy: A Randomized, Controlled Trial.
Salale N, Treldal C, Mogensen S, Rasmussen M, Petersen J, Andersen O, Jacobsen J.Clin Med Insights Gastroenterol. 2014 Oct 28;7:55-9. doi: 10.4137/CGast.S18019. eCollection 2014.PMID: 25374463 Free PMC article.